Riddhi Siddhi Gluco Biols Sets November 5 Results Meeting

Riddhi Siddhi Gluco Biols Limited will consider unaudited financial results for the quarter and half-year ended September 30, 2026, on November 5, following June-quarter revenue of ₹106.86 crore and net income of ₹3.27 crore. The meeting matters because it will provide the company’s next formal update after a June quarter that showed lower year-on-year revenue but a return to positive net income versus the preceding March quarter.

What will Riddhi Siddhi Gluco Biols consider on November 5?

Riddhi Siddhi Gluco Biols will consider and approve unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The board is also scheduled to adopt the limited review reports issued by the company’s statutory auditors.

The board-meeting intimation was dated November 2, 2026, and specified Thursday, November 5, 2026, as the meeting date. The disclosure identifies the results as the main agenda item. It does not provide an earnings estimate, operating outlook, or any proposed corporate action.

The company had earlier submitted unaudited standalone and consolidated results for the quarter ended June 30, 2026. Those results were considered by its board on August 13, 2026, along with the related limited review report.

Riddhi Siddhi Gluco Biols has also closed its insider-trading window from October 1, 2026. The restriction applies to designated persons and their relatives until 48 hours after the announcement of the unaudited September-quarter results, according to the information provided.

What did Riddhi Siddhi Gluco Biols report for the June 2026 quarter?

Riddhi Siddhi Gluco Biols reported consolidated revenue of ₹106.86 crore for the quarter ended June 30, 2026, compared with ₹175.78 crore in the year-earlier quarter. The company reported sales of ₹89.87 crore, against ₹154.61 crore a year earlier, based on the earnings-results figures supplied.

Net income for the June quarter was ₹3.27 crore, compared with ₹8.28 crore in the corresponding quarter of the prior year. Basic earnings per share were ₹4.21, compared with ₹11.27 a year earlier. Basic earnings per share from continuing operations were ₹5.37, against ₹13.46 in the prior-year quarter.

The supplied quarterly comparison also shows a sequential recovery from the March 2026 period, when revenue was stated at ₹20.06 crore and net profit at a loss of ₹32.74 crore. On that basis, June-quarter revenue increased 432.7% quarter on quarter, while the company returned to positive net profit.

Some data tables in the supplied material use different labels and figures for June 2026, including ₹89.87 crore as revenue and ₹13.51 crore as net profit. The earnings-results release separately identifies ₹89.87 crore as sales, ₹106.86 crore as revenue, and ₹3.27 crore as net income. Investors should rely on the filed standalone and consolidated financial statements and notes for the applicable reporting basis.

How have the company’s quarterly revenue figures moved?

Riddhi Siddhi Gluco Biols has reported volatile quarterly revenue in the supplied consolidated data. Revenue was ₹154.61 crore in June 2025, fell to ₹32.10 crore in September 2025, reached ₹40.08 crore in December 2025, and declined to ₹9.05 crore in March 2026 before rising to ₹89.87 crore in June 2026.

The company’s reported June 2026 sales of ₹89.87 crore were therefore substantially above the March 2026 sales figure of ₹9.05 crore. However, they remained below the June 2025 sales level of ₹154.61 crore. The upcoming September-quarter disclosure will provide the next comparable data point after this movement.

The source material also states that the company generally announces first-quarter results around mid-July, second-quarter results around mid-October, third-quarter results around mid-January, and fourth-quarter results around mid-April. The November 5 meeting is the stated date for the September 2026 quarter and half-year results.

Why does the September-quarter disclosure matter to investors?

The September-quarter results matter because they will show whether the sequential improvement reported for June continued into the next quarter. The June disclosure showed positive net income after the March-quarter loss, while year-on-year sales, revenue, net income, and earnings per share were lower than the comparable June 2025 period.

For investors, the audited or reviewed financial statements will be important for assessing the company’s revenue base, expenses, profitability and earnings per share on both standalone and consolidated bases. The limited review reports will also accompany the unaudited results considered by the board.

The announcement can also clarify the distinction between sales, revenue, operating metrics and net income used in different disclosures. Such distinctions are relevant when comparing quarter-on-quarter and year-on-year changes, especially where source tables present differently labelled figures.

Conclusion

Riddhi Siddhi Gluco Biols has scheduled its board meeting for November 5, 2026, to consider September-quarter and half-year financial results. Its latest reported June-quarter results showed revenue of ₹106.86 crore and net income of ₹3.27 crore, alongside lower year-on-year figures but an improvement from the March 2026 quarter.

The next item to watch is the company’s formal unaudited standalone and consolidated results for the quarter ended September 30, 2026, along with the statutory auditors’ limited review reports. The filing should provide the reported financial figures and the relevant basis for comparing them with prior periods.